Curis Announces Pricing of Public Offering of Common Stock

Rhea-AI Summary

Curis, Inc. (NASDAQ:CRIS) announced the pricing of a public offering of 25,652,174 shares at $5.75 per share, totaling approximately $147.5 million in gross proceeds. The offering is expected to close around December 11, 2020, pending customary conditions. Proceeds will be used for the development of CA-4948 and CI-8893, along with general working capital. The offering is made under a shelf registration statement and involves underwriters such as Cantor Fitzgerald & Co. and JonesTrading Institutional Services.

Positive

• Expected gross proceeds of approximately $147.5 million will fund the development of CA-4948 and CI-8893.
• Collaboration with Aurigene and ImmuNext may enhance research capabilities in oncology therapies.

Negative

• The public offering may result in shareholder dilution due to the increase in outstanding shares.

LEXINGTON, Mass., Dec. 9, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the pricing of an underwritten public offering of 25,652,174 shares of its common stock at a public offering price of $5.75 per share for total gross proceeds of approximately $147.5 million (the "Offering"). Curis has granted the underwriters a 30-day option to purchase up to an additional 3,847,826 shares of common stock on the same terms and conditions. The Offering is expected to close on or about December 11, 2020, subject to customary closing conditions.

Cantor Fitzgerald & Co. and JonesTrading Institutional Services LLC are acting as joint book-runners for the Offering.  H.C. Wainwright & Co., LLC and Laidlaw & Company (UK) Ltd. are acting as co-lead managers for the Offering.

Curis intends to use the net proceeds from the Offering, together with its existing cash and cash equivalents, to continue development of CA-4948, in collaboration with Aurigene, and CI-8893, in collaboration with ImmuNext, and for general working capital and capital expenditures.

The securities in the Offering are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-224627) that was filed with the United States Securities and Exchange Commission ("SEC") on May 3, 2018, and declared effective by the SEC on May 17, 2018 and an additional registration statement on Form S-3 (File No. 333-224627) filed pursuant to Rule 462(b) which became automatically effective on December 9, 2020.  A final prospectus supplement and accompanying prospectus relating to the Offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov.  Copies of the final prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6^th Floor, New York, New York 10022 or by email at prospectus@cantor.com.

The securities described above have not been qualified under any state blue sky laws.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Curis, Inc.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin's lymphoma and in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge^® for the treatment of advanced basal cell carcinoma. 

Forward-Looking Statements:  

Any statements in this press release about future expectations, plans and prospects for Curis, Inc., including  statements about Curis's anticipated closing of the Offering, anticipated use of proceeds from the Offering, and plans and prospectus for Curis, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "seek," "strategy," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to market and other conditions, the satisfaction of customary closing conditions related to the Offering and the impact of general economic, industry or political conditions in the United States or internationally. You should not place undue reliance on these forward-looking statements. Additional risks and uncertainties relating to the Offering, Curis and its business can be found under the caption "Risk Factors" included in Curis's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, Curis's prospectus supplement to be filed with the SEC, and in other filings that Curis periodically makes with the SEC. In addition, the forward-looking statements included in this press release represent Curis's views as of the date hereof. Curis anticipates that subsequent events and developments will cause Curis's views to change. However, while Curis may elect to update these forward-looking statements at some point in the future, Curis specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Curis's views as of any date subsequent to the date hereof.

View original content to download multimedia:http://www.prnewswire.com/news-releases/curis-announces-pricing-of-public-offering-of-common-stock-301189526.html

SOURCE Curis, Inc.

FAQ

What is the purpose of Curis's recent public offering?

Curis intends to use the proceeds from the public offering for the development of CA-4948 and CI-8893, as well as for general working capital.

What are the details of the common stock offering by Curis?

Curis is offering 25,652,174 shares at $5.75 per share, with total gross proceeds of approximately $147.5 million.

When is the closing date for the Curis public offering?

The closing of the public offering is expected around December 11, 2020.

Who are the underwriters for Curis's public offering?

Cantor Fitzgerald & Co. and JonesTrading Institutional Services LLC are acting as joint book-runners, with H.C. Wainwright & Co., and Laidlaw & Company as co-lead managers.